Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ADVM
- Price
- 4.36
- Stock movement up
- +- (0.00%)
- Company name
- Adverum Biotechnologies Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 96.26M
- Ent value
- 198.25M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -8.03%
- 1 year return (CAGR)
- -23.37%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2025-12-12
DIVIDENDS
ADVM does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | -55.07 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 22.08M |
| EPS (TTM) | -8.70 |
| FCF per share (TTM) | -5.89 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | -3.60M |
| Gross profit (TTM) | -1.68M |
| Operating income (TTM) | -207.32M |
| Net income (TTM) | -204.39M |
| EPS (TTM) | -8.70 |
| EPS (1y forward) | -4.16 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 46.75% |
| Operating margin (TTM) | 5758.78% |
| Profit margin (TTM) | 5677.56% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 26.06M |
| Net receivables | 0.00 |
| Total current assets | 28.91M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 58.24M |
| Total assets | 72.40M |
| Accounts payable | 12.46M |
| Short/Current long term debt | 88.94M |
| Total current liabilities | 44.75M |
| Total liabilities | 128.05M |
| Shareholder's equity | -55.65M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -137.90M |
| Capital expenditures (TTM) | 543.00K |
| Free cash flow (TTM) | -138.44M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -282.31% |
| Return on Invested Capital | 410.10% |
| Cash Return on Invested Capital | 277.78% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.24 |
| Daily high | 4.38 |
| Daily low | 4.23 |
| Daily Volume | 676K |
| All-time high | 600.80 |
| 1y analyst estimate | 4.88 |
| Beta | 0.87 |
| EPS (TTM) | -8.70 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ADVM | S&P500 | |
| Current price drop from All-time high | -99.27% | -0.63% |
| Highest price drop | -99.66% | -19.00% |
| Date of highest drop | 15 May 2025 | 8 Apr 2025 |
| Avg drop from high | -99.30% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 293 days | 89 days |
COMPANY DETAILS
Marketcap
96.26M
Marketcap category
Small-cap
Description
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Employees
155
Website
Investor relations
-
SEC filings
CEO
Leone D. Patterson
Country
USA
City
Redwood City
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner